Please provide your email address to receive an email when new articles are posted on . The oncolytic virus talimogene laherparepvec combined with neoadjuvant chemotherapy appeared safe and effective ...

Results from a phase 2 study suggests that the oncolytic virus talimogene laherparepvec has potential to improve therapy responses for patients undergoing neoadjuvant chemotherapy for triple-negative ...

Scientists have injected a human medical trial participant with a virus that is designed to kill cancer cells. The treatment is known as oncolytic virus therapy, in which a natural virus is ...

Gene therapy has experienced an increasing number of successful human clinical trials, leading to numerous FDA-approved therapies based on recombinant viruses for rare disease, cancer, and other ...

A single-arm IIT study of HA131 (hepatic arterial infusion) in combination with systemic therapy (XELOX with or without bevacizumab) as first-Line treatment in gastrointestinal cancer with liver ...

A team led by investigators at Mass General Brigham and Dana-Farber Cancer Institute has shown that a single injection of an oncolytic virus—a genetically modified virus that selectively infects and ...

Investigators from Brigham and Women’s Hospital reported the results of a Phase I clinical trial evaluating a novel engineered oncolytic herpes virus (oHSV) in patients with high-grade recurrent ...

TAMP enables localized, targeted delivery of CF33 to difficult-to-access tumors, such as pancreatic and liver tumors. “We believe the synergy between RenovoRx’s trans-arterial drug delivery system and ...

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Oncolytic Virus Therapy Market & Pipeline Outlook 2022" report to their offering. Global Oncolytic Virus Therapy ...

Jianmei Leavenworth, M.D., Ph.D., associate professor in the Department of Neurosurgery, has been named the latest recipient of the school’s Fea Jianmei Leavenworth, M.D., Ph.D.tured Discovery award.

The oncolytic virus therapy landscape has expanded steadily over the past decade, with over 100 companies worldwide pursuing clinical or preclinical programs. A few leaders, such as Candel ...